Cardiac Resynchronization Therapy Market Outlook 2022 to 2032: Growth Insights with Medtronic, Abbott, Boston Scientific, Biotronik and Others

Newly-released Cardiac Resynchronization Therapy industry analysis report by Fact.MR shows that global sales of Cardiac Resynchronization Therapy (CRT) in 2021 were held at US$ 5.7 billion. The industry is expected to witness a compound annual growth rate (CAGR) of 7.9% from 2022 to 2032, slightly lower than the historical rate. Notably, CRT-Defibrillator is poised to lead the market, creating an absolute dollar opportunity of nearly US$ 4 billion over the next decade, driven by increasing adoption for advanced cardiac care and reduction in heart failure-related hospitalizations.

Browse Full Report: https://www.factmr.com/report/cardiac-resynchronization-therapy-market

Surge in Heart Failure Prevalence Fuels Demand for Cardiac Resynchronization Therapy

Cardiac resynchronization therapy (CRT) has emerged as a life-saving intervention for patients suffering from heart failure with reduced ejection fraction (HFrEF). The increasing global burden of heart failure-due to lifestyle-related disorders such as hypertension, obesity, diabetes, and aging populations-is a major driver for the CRT market. The therapy works by using a specialized pacemaker or defibrillator to coordinate the contractions of the heart's ventricles, improving blood flow and patient outcomes.

With over 26 million people globally living with heart failure, the clinical importance of CRT devices continues to expand. CRT is now widely recommended for patients with prolonged QRS durations and symptoms of advanced heart failure, improving not only survival but also quality of life.

CRT-Defibrillator (CRT-D) Segment Dominates Product Landscape

Among product types, the CRT-Defibrillator segment dominates the global market, contributing significantly to overall revenue. CRT-D devices combine pacing therapy with an implantable cardioverter defibrillator (ICD), providing both synchronization and life-saving shock therapy during dangerous arrhythmias. The segment is expected to see robust growth and generate approximately US$ 4 billion in additional revenue from 2022 to 2032.

In contrast, CRT-Pacemakers (CRT-P) continue to hold a modest share but are still relevant for patients who do not require defibrillation. These devices are preferred for elderly or low-risk patients, offering benefits at a lower cost. However, technological enhancements and increasing patient eligibility have tilted market preference toward CRT-Ds.

Hospitals Remain Leading End-users; Home Care Segment Gaining Ground

By end-user type, hospitals remain the primary channel for CRT procedures due to the complexity of device implantation, need for specialized equipment, and post-procedure monitoring. As tertiary care centers offer advanced cardiac programs, they are expected to maintain dominance in the CRT space throughout the forecast period.

However, the home care segment is gaining traction, particularly in North America and parts of Europe, where remote patient monitoring and telemedicine integration have expanded post-COVID-19. CRT device manufacturers are responding with Bluetooth-enabled and remotely programmable devices, improving long-term patient care and therapy adherence.

North America Leads the CRT Market, Driven by Advanced Healthcare Infrastructure

Regionally, North America commands the largest share of the cardiac resynchronization therapy market, led by the United States. High prevalence of cardiac diseases, a growing aging population, well-established reimbursement policies, and early adoption of advanced technologies contribute to this dominance. The U.S. alone accounted for a significant portion of CRT implantations globally in 2021.

Europe follows closely, driven by increasing awareness of cardiac care and consistent regulatory approvals. Meanwhile, Asia Pacific is projected to witness the highest growth rate during the forecast period due to expanding healthcare infrastructure, growing medical tourism in India and Thailand, and increasing government investment in cardiac health programs.

Key Players and Competitive Landscape: Strategic Mergers, Product Launches Drive Growth

The cardiac resynchronization therapy market is highly consolidated, with a few major players controlling a substantial market share. Key players are focusing on strategic acquisitions, partnerships, and technological innovation to maintain their competitive edge.

Major players include:

- Medtronic plc - Known for its extensive CRT-D and CRT-P portfolio, Medtronic continues to lead the market through frequent product upgrades and remote monitoring solutions.

- Abbott Laboratories - With its innovative CRT offerings under the AssurityTM and Quadra AssuraTM lines, Abbott emphasizes patient-centric design and smart connectivity.

- Boston Scientific Corporation - A pioneer in defibrillator technology, Boston Scientific is focusing on miniaturization, improved battery life, and MRI-safe devices.

- Biotronik SE & Co. KG - Strong in the European market, Biotronik has made significant strides in developing intuitive CRT devices compatible with advanced diagnostics.

- MicroPort Scientific Corporation - Rapidly emerging in the Asia-Pacific CRT landscape, MicroPort is investing in R&D and localized manufacturing for cost-efficient therapies.

Recent developments include Boston Scientific's launch of next-generation CRT devices with multisite pacing capabilities, and Abbott's expansion of its remote device management ecosystem, strengthening its position in outpatient and home-based CRT management.

Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7166

Outlook: Technological Innovation and Global Heart Health Awareness to Accelerate Growth

With growing awareness about cardiac health, rising global cases of heart failure, and technological advancements in device design, the Cardiac Resynchronization Therapy market is expected to reach US$ 12.4 billion by 2032. The convergence of artificial intelligence, remote care, and miniaturized hardware is likely to define the next era of CRT.

As the market continues to evolve, manufacturers must focus on improving device longevity, patient comfort, and integration with digital health platforms. With continued investment and cross-sector collaborations, CRT devices will remain pivotal in reducing mortality and enhancing lives globally.

Check out More Related Studies Published by Fact.MR Research:

Acute Care Market: https://www.factmr.com/report/acute-care-market

Rehabilitation Robots Market : https://www.factmr.com/report/rehabilitation-robots-market

Vertical Platform Lift Market: https://www.factmr.com/report/vertical-platform-lift-market

Brush Rocker Market: https://www.factmr.com/report/brush-rocker-market

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team : sales@factmr.com

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

This release was published on openPR.